Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
CNBC

Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Summary from CNBC
Read the full story on CNBCFollow















